论文部分内容阅读
目的:研究参灵固本丸联合化疗治疗晚期非小细胞肺癌疗效。方法:将91例住院患者随机分为两组,对照组应用GP方案化疗,治疗组患者应用参灵固本丸5 g,日3次口服。化疗药剂量及用法同对照组,治疗14 d为1疗程。行4周期化疗后观察患者临床症状、体力状况评分、化疗不良反应,判定疗效。并通过生存期(平均生存期、1年生存率)判断远期临床疗效。结果:治疗组(62.2%)有效率优于对照组(41.3%),具有显著性差异(P<0.01);治疗后,治疗组卡氏评分高于对照组(P<0.01),治疗组恶心呕吐、腹泻症状改善,白细胞减少发生率优于对照组(P<0.05),皮疹、血小板减少及肝肾功能损害改善方面,两组间无明显差异(P>0.05)。结论:参灵固本丸联合化疗治疗晚期非小细胞肺癌,可明确减轻化疗毒副作用,缓解不良反应,有效改善患者生存质量,延长生存期,提高远期临床疗效。
Objective: To study the effect of Shenling Guben Pills combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods: Ninety-one inpatients were randomly divided into two groups. The control group received chemotherapy with GP regimen. The patients in the treatment group received Shenling Guben Pills (5g) orally for 3 times daily. The dosage and usage of chemotherapeutic drugs were the same as the control group, and the treatment for 14 days was a course of treatment. After 4 cycles of chemotherapy, the patients were observed for clinical symptoms, physical status scores, adverse reactions of chemotherapy, and the curative effect. And through the survival (mean survival, 1-year survival rate) to determine the long-term clinical efficacy. Results: The effective rate of the treatment group (62.2%) was significantly higher than that of the control group (41.3%) (P <0.01). After treatment, the Karnofstal score of the treatment group was higher than that of the control group (P <0.01) Vomiting, diarrhea, leucopenia incidence was better than the control group (P <0.05), rash, thrombocytopenia and liver and kidney dysfunction improved, there was no significant difference between the two groups (P> 0.05). Conclusion: Shenling Guben Pill combined with chemotherapy in the treatment of advanced non-small cell lung cancer can obviously relieve side effects of chemotherapy, relieve adverse reactions, effectively improve patients’ quality of life, prolong survival and improve long-term clinical efficacy.